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Organ transplant recipients (OTRs) have a high inci-
dence of cutaneous squamous cell carcinoma (cSCC), 
and immunosuppression has been reported to be an 
important risk factor for metastasis. The aim of this 
study was to identify the metastasis risk over a 10-
year period for 593 patients with cSCC, of whom 134 
were OTR and 459 were immunocompetent. Metasta-
sis incidence rate was 1,046 (95% confidence inter-
val (95% CI) 524–2,096) per 100,000 person years 
in OTR and 656 (95% CI; 388–1,107) in immunocom-
petent patients, yielding an incidence rate ratio of 1.6 
(95% CI 0.67–3.81). In OTRs head/neck location, ol-
der age at transplantation and older age at diagnosis 
of first cSCC were associated with metastatic risk, and 
7 out of 8 metastasized tumours were smaller than 2 
cm. In immunocompetent patients tumour size and tu-
mour depth were associated with metastasis. In con-
clusion, we were not able to demonstrate an increased 
incidence rate of metastasis in OTRs compared with 
immunocompetent patients. However, OTRs and im-
munocompetent patients differed with regard to risk 
factors for metastasis.
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Cutaneous squamous cell carcinoma (cSCC) is the se-cond most frequent form of keratinocyte carcinoma 
(KC) (1, 2). The incidence of cSCC varies globally, with 
a higher incidence closer to the equator. In Finland the 
reported incidence for men is 6 per 100,000 person years 
and for women 4 per 100,000 person years. In Austra-
lia, these numbers are reported to be 1,035 and 472 per 
100,000 person years, respectively (3, 4). 
The incidence of cSCC metastasis varies, with higher 
incidence often reported from tertiary hospitals (5–10). 
The risk of developing metastasis from low-risk cSCC 
in the general population is between 0.5% and 5%, but 
may be as high as 45% in high-risk cSCC, i.e. tumours 
located on the lip and ear, large tumours and recurrent 
tumours (5, 11, 12).
The risk of developing cSCC in organ transplant 
recipients (OTRs) is 40–250 times increased compared 
with the general population (13). In some reports, it has 
been suggested that cSCC in OTRs frequently exhibit 
aggressive behaviour irrespective of size, that in-transit 
metastases are more frequent, and that cSCC in OTRs 
have a worse prognosis than cSCC in immunocompetent 
patients (14, 15). Between 5% and 23% of all patients 
with metastatic cSCC, have been reported to be immu-
nosuppressed, many of whom were OTR, and therefore 
immunosuppression has been reported to be a risk factor 
for metastasis (16–18). 
In clinical practice, it is difficult to identify high-risk 
cSCC and to detect metastasis at an early stage, both 
in immunosuppressed and immunocompetent patients 
(19–21). Tumour size, Clark’s level, Breslow’s thickness, 
degree of differentiation, perineural invasion and location 
are associated with the development of metastasis (22). 
Staging systems are developed to help determine high-
risk tumours (23–25). The American Joint Committee on 
Cancer (AJCC) classification is the most commonly used 
staging system, and is subject to regular modifications. 
Since 2010 the AJCC classification is based on several 
high-risk features of cSCC (23). Though immunosup-
pression is mentioned as a risk factor, it does not influence 
tumour stage in any of the staging systems. 
OTR are subject to lifelong immunosuppressive 
therapy and therefore are an ideal population with regard 
to analysing the influence of immunosuppression on 
cSCC metastatic behaviour. Comparative studies between 
OTR and immunocompetent patients focusing on the me-
tastasis risk of cSCC are scarce. The aim of this study was 
to identify the risk of cSCC metastasis in a defined cohort 
of OTRs and immunocompetent patients, calculated both 
per patient as well as per individual tumour.
METHODS
For this retrospective study, all consecutive patients with primary 
cSCC who were diagnosed from January 2004 to December 2013 
were identified from the institutional oncology database of Leiden 
University Medical Centre. Each patient’s medical record was 
cross-checked with pathology records of cSCC in the same pe-
riod. Missing patients and/or tumours were added to the database 
manually. Each tumour was given its own record; one individual 
patient could have had more records in case of multiple primary 
Metastasis Risk of Cutaneous Squamous Cell Carcinoma in Organ 
Transplant Recipients and Immunocompetent Patients
Roel E. GENDERS1, Joris A. J. OSINGA1, Elise E. TROMP1, Peter O’ROURKE2, Jan N. BOUWES BAVINCK1 and Elsemieke I. 
PLASMEIJER1,3
1Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands, 2Statistics Unit, and 3Cancer and Population studies, 
























































R. E. Genders et al.552
www.medicaljournals.se/acta
cSCC. Detailed histopathological information on all tumours was 
extracted from the Dutch pathology registry (PALGA). Tumours 
were categorized by differentiation grade (good, moderate, poor, 
undifferentiated), presence of lymphovascular invasion, presence 
of perineural invasion, tumour depth, location and tumour size 
(26). All tumours were classified using the TNM staging clas-
sification (AJCC 7th edition).
Patient data were extracted from the institutional oncology da-
tabase. When missing, additional data were collected from patient 
files. Status and data of immunosuppression were retrieved from 
the institutional patient database and patient files. 
Patient files for all patients were checked for information on 
possible development of metastasis in December 2015, i.e. a 
minimum follow-up of 2 years. In case of metastasis, the cSCC 
that was most likely to be the index tumour was identified. Cases 
were defined as patients who developed a metastasis from a cSCC 
that was diagnosed during the study period. 
Follow-up time was defined as the time from cSCC diagnosis to 
diagnosis of metastasis, death or end of study or to censoring. In 
our institution OTRs were examined at least every 3 months. Im-
munocompetent patients were followed clinically based on tumour 
stage according to national guidelines, i.e. twice a year for the first 
1–2 years and once a year in year 3–5 for patients with low-risk 
cSCC, and every 3 months first year, every 4, 6 and 12 months in 
year 2, 3 and 4–5, respectively for patients with high-risk cSCC. 
Screening for metastasis was performed routinely by lymph node 
palpation, and on indication in high-risk tumours by radiological 
imaging (ultrasound, X-ray, magnetic resonance imaging (MRI), 
computed tomography (CT) or positron emission tomography 
(PET) scan). Sentinel lymph node procedure was not performed. 
Descriptive statistics were used for patient and tumour cha-
racteristics at baseline. Frequencies, percentages, median, mean 
and range were calculated, when appropriate. Patients that were 
immunosuppressed for other reasons than organ transplantation 
were excluded. Univariable Cox regression analysis was used to 
identify risk factors for metastasis, excluding cases with missing 
values for each variable. Multivariable analyses were not carried 
out due to limited number of events. A p-value < 0.05 was set as 
statistically significant for all analyses. Statistical analysis was 
performed using SPSS version 23 (SPSS, Chicago, IL, USA). 
Incidence rate per person year of metastasis was calculated using 
STATA 13.1.
RESULTS
During the follow-up time of median 4.0 years (range 1 
month–10.8 years), 1,792 cSCCs were diagnosed in 665 
patients, with up to 116 cSCCs in one patient. After ex-
clusion of one OTR who had developed a cSCC one year 
before transplantation, 66 patients who were immuno-
suppressed for reasons other than organ transplantation 
(inflammatory disease or haematological malignancy) 
and 6 patients who had developed a metastasis from a 
cSCC diagnosed prior to the study period, the study co-
hort consisted of 134 OTRs and 459 immunocompetent 
patients (Table I). 
In all, 23 patients (3.9%; 95% CI 2.6–5.8) developed 
a metastasis from a cSCC diagnosed in the study period, 
8 (6.0; 95% CI 3.1–11.3) OTRs and 15 (3.3%; 95% CI 
2.0–5.3) immunocompetent patients. The incidence 
rate (IR) for metastasis was 1,046 (95% CI 524–2,096) 
per 100,000 person years in the OTR group and 656 
(95% CI; 388–1,107) in the immunocompetent patient 
group, yielding an incidence rate ratio (IRR) between 
OTRs vs. immunocompetent patients of 1.6 (95% CI 
0.67–3.8). Median time between cSCC diagnosis and 
metastasis diagnosis was longer in the OTR group than 
in the immunocompetent group, 17.5 and 10.5 months, 
respectively. Distant site metastasis was found in 1 OTR 
and in 5 immunocompetent patients, of whom 3 also had 
concomitant nodal metastasis. 
Patient, tumour and metastasis characteristics are 
shown in Table II and Table III. Univariate hazard ra-
tios for metastasis are listed in Table III. Having a first 
cSCC at an older age was significantly associated with 
an increased risk of metastasis in OTRs (Hazard ratio 
(HR) 8.3, 95% CI: 1.7–41.8). In the immunocompe-
tent group, all patients (15) with metastasis developed 
their first cSCC after the age of 60 years. In OTRs, 
being transplanted at 60 years or older (HR 5.0, 95% 
CI 1.2–21.7), increased the risk of metastasis. Having 
multiple cSCCs was not associated with increased risk 
for metastasis in either group. cSCC located in the head 
and neck area was a risk factor for metastasis, both in 
the OTR group (HR 16.9, 95% CI 2.1–138.5) and in the 
immunocompetent group (HR 3.8, 95% CI 0.85–16.9), 
but statistically significant only in the OTR group. In the 
OTR group T stage, tumour size, differentiation grade 
and depth of invasion were not associated with increased 
metastasis risk. T stage of 2 or higher, tumour size and 
tumour depth beyond the dermis were associated with 
increased risk of metastasis in the immunocompetent 
group. In the OTR group, perineural invasion was not 
found in any metastatic cSCC and in 3 non-metastatic 
cSCC, but was observed in 1 metastatic cSCC and in 9 
non-metastatic cSCC in the immunocompetent popula-
tion. Lymphovascular invasion was only seen in 1 non-
metastatic cSCC in OTR and in 2 non-metastatic cSCC 
in immunocompetent patients. 
Table I. Baseline characteristics of 593 patients with cutaneous 








Female 40 (30) 188 (41)
Male 94 (70) 271 (59)
Age first lifetime cSCC
< 60 years 90 (67) 78 (17)
≥ 60 years 44 (33) 381 (83)
Number cSCC study period, mean/patient   6.2 1.8
1 39 (29) 357 (78)
2–5 58 (43) 91 (20)
> 5 37 (28) 11 (2)
Number lifetime cSCC, mean/patient   8.6 2.4
1 32 (24) 313 (68)
2–5 52 (39) 130 (28)
> 5 50 (37) 16 (4)
Type of transplantation
Kidney 110 (82) NA
Kidney-pancreas 17 (13) NA
Liver   7 (5) NA

























































553Metastasis risk of cutaneous squamous cell carcinoma
Acta Derm Venereol 2018
Table III. Univariate hazard ratios for patient and tumour characteristics as risk factors for metastasis in patients with cutaneous 
squamous cell carcinoma (cSCC)








n (%) HR (95% CI)
Patients 134 8 459 15
Sex     
Female 40 1 (2) 1 188   5 (3) 1
  Male 94 7 (7) 4.4 (0.52–36.1) 271 10 (4) 1.4 (0.49–4.2)
Age at 1st cSCC     
< 60 years 90 2 (2) 1   78   0 Not applicable
≥ 60 years 44 6 (14) 8.3 (1.7–41.8) 381 15 (4) Not applicable
Number cSCC study period     
1 39 1 (3) 1 357 12 (3) 1
> 1 95 7 (7) 1.5 (0.19–12.8) 102   3 (3) 0.75 (0.21–2.7)
Number lifetime cSCC 
1 33 2 (6) 1 314 12 (4) 1
> 1 101 6 (6) 0.48 (0.09–2.6) 145   3 (2) 0.49 (0.14–1.7)
Age at transplantation
< 60 years 113 5 (4) 1 Not applicable Not applicable Not applicable
≥ 60 years   21 3 (14) 5.0 (1.2–21.7) Not applicable Not applicable Not applicable
Tumours 829 8 814 15
Location tumour
Body 582 1 (1) 1 296   2 (1) 1
Head & neck 247 7 (3) 16.9 (2.1–138.5) 518 13 (3) 3.8 (0.85–16.9)
T-stage
T1 657 6 (1) 1 584   1 (1) 1
T2–T4 73 1 (1) 1.5 (0.18–12.7) 105 10 (10) 61.4 (7.8–484.9)
Missing 99 1 (1)  125 4 (3)
Tumour size (diameter)
≤ 20 mm 726 7 (1) 1 661 6 (1) 1
> 20 mm 59 1 (2) 1.8 (0.21–14.6) 71 6 (8) 10.1 (3.2–32.1)
Missing 44 0  82 3 (4)
Differentiation
Good–moderate 720 7 (1) 1 681 10 (1) 1
Poor–undifferentiated 94 1 (1) 1.1 (0.13–9.0) 120 4 (3) 2.3 (0.71–7.5)
Missing 15 0    13 1 (8)
Depth/invasion
Dermis 227 4 (2.0) 1 458 3 (1) 1
Hypodermis   27 1 (4) 1.4 (0.24–8.5)   46 8 (17) 6.5 (3.3–13.0)
Missing 575 3 (1)  310 4 (1)  
CI: confidence interval; HR: hazard ratio.

























F 43 Kidney/pancreas Cheek 14 Good Unknown 1 8 Nodal 27 months No
M 61 Kidney Scalp 10 Good Subcutis 1 3 Nodal 14 months No
M 62 Kidney/pancreas Chest 14 Undifferentiated Unknown Unk. 8 Nodal 3 months Yes
M 66 Kidney Frontal 15 Good Unknown 1 1 Nodal 3 months Alive
M 68 Kidney Peri-ocular 16 Good Dermis 1 3 Distant 30 months No
M 68 Liver Neck 17 Good Dermis 1 1 Nodal 21 months Cause unk.
M 70 Kidney/pancreas Ear 25 Good Dermis 2 15 Nodal   6 months Alive
M 71 Kidney Scalp 15 Good Dermis 1 15 Nodal 38 months Alive
F 65 No Finger 10 Poor Unknown Unk. 1 Nodal 17 months Yes
M 66 No Temporal 10 Undifferentiated Muscle 3 1 Distant 13 months Yes
F 72 No Cutaneous lip 16 Good Muscle 3 1 Nodal & distant 16 months Yes
M 74 No Temporal Unknown Moderate Dermis Unk. 1 Nodal   7 months Yes
M 75 No Ear 25 Good Muscle 3 1 Nodal 21 months Alive
M 76 No Scalp Unknown Good Unknown Unk. 1 Distant 7 months Cause unk.
F 79 No Peri-ocular 38 Undifferentiated Unknown 2 1 Nodal 6 months No
F 84 No Arm Unknown Poor Unknown Unk. 11 Nodal 2 months No
F 85 No Temporal 45 Good Dermis 2 1 Nodal 7 months Alive
M 85 No Frontal 15 Moderate Muscle 3 1 Nodal 39 months Cause unk.
M 85 No Occipital 45 Good Subcutis 2 5 Nodal & distant   0 months Yes
M 86 No Neck 15 Unclassifiable Dermis 1 1 Nodal 15 months No
Ma 88 No Temporal 32 Good Subcutis 2 1 Nodal & distant   1 months Yes
M 93 No Ear 19 Good Cartilage 3 6 Nodal 13 months Yes
M 94 No Ear 30 Moderate Subcutis 2 1 Nodal   8 months Cause unk.
aOnly patient without perineural invasion
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DISCUSSION
This study was not able to demonstrate a significantly 
increased risk for metastasis from cSCC in OTRs com-
pared with immunocompetent patients with cSCC. Ho-
wever, the risk factors appeared to be different between 
the 2 groups. 
With cSCC metastases incidences of 6.0% in OTR and 
3.3% in the immunocompetent patients the incidence 
of metastasis from this study was lower than in other 
studies. In OTR metastases incidences of 7–14% are 
reported for low-risk tumours and 10–20% for high-risk 
tumours (1, 9, 18, 27–30). In the general population, the 
overall incidence varies between 2.3% and 9.9% (31). 
For low-risk tumours the risk is between 0.5% and 5% 
and may increase to more than 20% in high-risk cSCC 
(5, 11, 12). 
The mean time between diagnosing the cSCC and 
detecting metastasis was longer in the OTR group than 
in the immunocompetent group. The OTR group had 
a median time of 17.5 months to develop metastasis, 
compared with 10.5 months in the immunocompetent 
group. This was a surprising finding, considering both 
the immunosuppressed state leading to decreased immu-
nological tumour surveillance and the increased clinical 
surveillance of OTRs. As the majority of tumours in 
OTRs were not located in the head and neck area, in 
contrast to the immunocompetent group, this difference 
in tumour distribution could contribute to the relatively 
low risk of metastasis in OTRs. In other studies, the 
median time to develop metastasis is reported from 4 to 
12 months (32, 33).
In OTR, age over 60 years at transplantation and 
at time of first cSCC diagnosis were risk factors for 
metastasis. This is in line with previous studies (34). 
As OTRs developed their first cSCC at a younger age 
than immunocompetent patients, this could explain the 
relatively low number of metastasis in OTRs. Most 
OTRs in our study were renal transplant recipients and 
have somewhat different immunosuppressive treatment 
regimens than other OTRs, especially heart transplant 
recipients (35–37). This could contribute to different 
incidence rates of cSCC metastasis across the literature.
In our immunocompetent patients, tumour size and 
depth, and subsequently T-stage, were significant risk 
factors for metastasis, as shown in other studies (5, 9, 28, 
38, 39). In our OTRs we did not find these associations. 
Tumour size is a well-known risk factor for metastatic 
lesions (5, 9, 19, 40–43) with an association between 
increasing tumour thickness and lesion size (18). In our 
study, 7 out of 8 cSCC that metastasized in OTR were 
less than 2 cm in diameter and most of the tumours 
were low-risk T1 tumours. This suggests that OTRs 
with relatively small tumours (<2 cm) are already at an 
increased risk of developing metastasis from cSCC, and 
are less dependent on specific tumour characteristics (18, 
44). OTRs have regular clinical follow-ups, and small 
tumours should therefore be diagnosed before they grow 
into large tumours. Although it is published that patients 
with multiple cSCC are at an increased risk of metastasis 
(45), we were unable to confirm that having multiple 
tumours led to a higher risk of metastasis. Given the 
low number of metastases in our OTR group and with 
metastases developing mainly from relatively small 
tumours, frequent follow-up of OTRs should continue. 
This study has several limitations. First, there was only 
a small number of patients with metastasizing cSCCs in 
the OTR group. It was, therefore, difficult to estimate 
the effect size for risk factors. We acknowledge that 
statistical analysis should be considered insufficient and 
only indicative. We also had too few cases to perform 
multivariable analyses to control for possible confoun-
ders. Secondly, the Leiden University Medical Centre is 
a tertiary referral centre for selected patients with cSCC. 
Due to this selection bias, extrapolation of our results is 
difficult, as one should expect a higher rate of metasta-
sis in immunocompetent patients with cSCC referred 
to the hospital. Finally, the cSCCs in our cohort were 
diagnosed by several pathologists without a systematic 
re-evaluation of the histopathological slides. This might 
have introduced some error, but probably not bias, as no 
differences are expected in how pathologists will evaluate 
tumours from OTRs and immunocompetent patients. 
To conclude, the metastatic rate of cSCC in OTRs and 
immunocompetent patients in this study is lower than 
in most other studies. We were not able to demonstrate 
an increased risk of metastasis in OTRs compared with 
immunocompetent patients. Most tumours that did me-
tastasize in OTRs were small tumours without high-risk 
features. Close and regular inspection of the skin with 
adequate and rapid diagnosis and treatment of cSCC is 
important to prevent metastasis. 
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